{
    "code": "02024692",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024692",
    "time": "2017-04-14 03:29:45",
    "許可證字號": "衛署藥輸字第024692號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "106\/09\/10",
    "發證日期": "96\/09\/10",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202469202",
    "中文品名": "骨力強注射液5毫克\/100毫升",
    "英文品名": "Aclasta 5mg\/100ml Solution for infusion",
    "適應症": "治療骨佩吉特氏病 (Paget's disease of bone)治療停經後婦女的骨質疏鬆症，以降低發生髖關節、脊椎與非脊椎性骨折的機率，並增加骨密度。男性骨質疏鬆症之治療，以增加骨密度。Aclasta適用於治&#63937;及預防男性與&#63873;性因&#63952;固醇引起之骨質疏鬆症；這些病患為剛開始使用或持續使用每日劑&#63870;相當於7.5 mg prednisolone或&#63745;高劑&#63870;的全身性&#63952;固醇，且預期將持續使用&#63952;固醇至少12個月者。Aclasta預防停經後婦女的骨質疏鬆症。",
    "劑型": "270注射劑",
    "包裝": "100毫升注射塑膠瓶裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "ZOLEDRONICACID"
    ],
    "限制項目": "02輸　入",
    "申請商名稱": "0901301200  美時化學製藥股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F430088000  NOVARTIS PHARMA STEIN AG",
        "製造廠廠址": "SCHAFFHAUSERSTRASSE CH-4332 STEIN, SWITZERLAND",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "6400001600",
            "成分名稱": "ZOLEDRONIC ACID",
            "含量描述": "(monohydrate 0.0533mg)",
            "含量": "0.0500000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "020246920001-106-02-14.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024692&Seq=006&Type=9"
        },
        {
            "title": "Aclasta 2-104-09-16(廠商自行上傳).pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024692&Seq=006&Type=8"
        }
    ]
}